182 related articles for article (PubMed ID: 20481176)
41. The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain.
Kang JH; Oh SY; Song SY; Lee HY; Kim JH; Lee KE; Lee HR; Hwang IG; Park SH; Kim WS; Park YS; Park K
Korean J Intern Med; 2015 Jan; 30(1):88-95. PubMed ID: 25589840
[TBL] [Abstract][Full Text] [Related]
42. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
43. [Opioid intoxication. Inappropriate administration of transdermal fentanyl].
Klockgether-Radke A; Hildebrandt J
Anaesthesist; 1997 May; 46(5):428-9. PubMed ID: 9245212
[TBL] [Abstract][Full Text] [Related]
44. Towards Evidence-Based Weaning: a Mechanism-Based Pharmacometric Model to Characterize Iatrogenic Withdrawal Syndrome in Critically Ill Children.
Goulooze SC; Ista E; van Dijk M; Tibboel D; Krekels EHJ; Knibbe CAJ
AAPS J; 2021 May; 23(4):71. PubMed ID: 34002290
[TBL] [Abstract][Full Text] [Related]
45. Opioid-associated amnestic syndrome observed with fentanyl patch use.
Taylor RG; Budhram A; Lee DH; Mirsattari SM
CMAJ; 2019 Mar; 191(12):E337-E339. PubMed ID: 30910881
[No Abstract] [Full Text] [Related]
46. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial.
Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L
Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851
[TBL] [Abstract][Full Text] [Related]
47. Inappropriate use of high doses of transdermal fentanyl at admission to a palliative care unit.
Botterman J; Criel N
Palliat Med; 2011 Mar; 25(2):111-6. PubMed ID: 20937611
[TBL] [Abstract][Full Text] [Related]
48. Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method.
Azar P; Nikoo M; Miles I
Am J Addict; 2018 Dec; 27(8):601-604. PubMed ID: 30387894
[TBL] [Abstract][Full Text] [Related]
49. Fentanyl patch for stable chronic pain in children: new indication. Used fentanyl patches should be handled with care.
Prescrire Int; 2008 Jun; 17(95):104. PubMed ID: 18623912
[TBL] [Abstract][Full Text] [Related]
50. Perioperative opiate requirements in children with previous opiate infusion.
Fanning JJ; Stucke AG; Christensen MA; Cassidy LD; Berens RJ
Paediatr Anaesth; 2012 Mar; 22(3):203-8. PubMed ID: 22070472
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of the fentanyl iontophoretic transdermal system (ITS) and intravenous patient-controlled analgesia (IV PCA) with morphine for pain management following abdominal or pelvic surgery.
Minkowitz HS; Rathmell JP; Vallow S; Gargiulo K; Damaraju CV; Hewitt DJ
Pain Med; 2007; 8(8):657-68. PubMed ID: 18028044
[TBL] [Abstract][Full Text] [Related]
52. Predicting long-term response to strong opioids in patients with low back pain: findings from a randomized, controlled trial of transdermal fentanyl and morphine.
Kalso E; Simpson KH; Slappendel R; Dejonckheere J; Richarz U
BMC Med; 2007 Dec; 5():39. PubMed ID: 18154644
[TBL] [Abstract][Full Text] [Related]
53. Transdermal fentanyl in children with cancer pain: feasibility, tolerability, and pharmacokinetic correlates.
Collins JJ; Dunkel IJ; Gupta SK; Inturrisi CE; Lapin J; Palmer LN; Weinstein SM; Portenoy RK
J Pediatr; 1999 Mar; 134(3):319-23. PubMed ID: 10064669
[TBL] [Abstract][Full Text] [Related]
54. Transdermal fentanyl in postoperative pain.
Lehmann LJ; DeSio JM; Radvany T; Bikhazi GB
Reg Anesth; 1997; 22(1):24-8. PubMed ID: 9010943
[TBL] [Abstract][Full Text] [Related]
55. Withdrawal symptoms in critically ill children after long-term administration of sedatives and/or analgesics: a first evaluation.
Ista E; van Dijk M; Gamel C; Tibboel D; de Hoog M
Crit Care Med; 2008 Aug; 36(8):2427-32. PubMed ID: 18596622
[TBL] [Abstract][Full Text] [Related]
56. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
Sittl R; Nuijten M; Nautrup BP
Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
[TBL] [Abstract][Full Text] [Related]
57. Characterisation of the pharmacokinetics of the fentanyl HCl patient-controlled transdermal system (PCTS): effect of current magnitude and multiple-day dosing and comparison with IV fentanyl administration.
Sathyan G; Jaskowiak J; Evashenk M; Gupta S
Clin Pharmacokinet; 2005; 44 Suppl 1():7-15. PubMed ID: 16156111
[TBL] [Abstract][Full Text] [Related]
58. Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.
Alberts DS; Smith CC; Parikh N; Rauck RL
Pain Manag; 2016 Oct; 6(5):427-34. PubMed ID: 27020837
[TBL] [Abstract][Full Text] [Related]
59. Tolerance and withdrawal from prolonged opioid use in critically ill children.
Anand KJ; Willson DF; Berger J; Harrison R; Meert KL; Zimmerman J; Carcillo J; Newth CJ; Prodhan P; Dean JM; Nicholson C;
Pediatrics; 2010 May; 125(5):e1208-25. PubMed ID: 20403936
[TBL] [Abstract][Full Text] [Related]
60. Heat-related toxicity with the fentanyl transdermal patch.
Newshan G
J Pain Symptom Manage; 1998 Nov; 16(5):277-8. PubMed ID: 9846020
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
